Equipoise (Boldenone): Lean Mass Research Guide

Equipoise (boldenone undecylenate, usually just called EQ) is a long-acting injectable androgen with a reputation for slow, lean gains and notable endurance effects. The short answer: it is a testosterone analog with a double bond at the 1,4 position that reduces both androgenic and estrogenic activity, has a 14-day half-life, and drives steady erythropoiesis (red blood cell production). It is not hepatotoxic and has a comparatively mild side-effect profile, but it carries an exceptionally long detection window and raises hematocrit over time. EQ is a marathon, not a sprint.

What Equipoise is and how it differs from testosterone

Boldenone Undecylenate (Equipoise) is boldenone with the undecylenate ester attached. Boldenone itself is a testosterone analog with a double bond at the 1,2 position. That single structural change reduces both androgenic and estrogenic activity relative to testosterone. It still aromatizes, but weakly, roughly half the rate of testosterone.

The compound was originally developed for veterinary use. It had a brief human run as Parenabol before being pulled, then lived on as Equipoise for horses. Most of what is available now comes from veterinary or underground sources.

Two effects define boldenone’s character. It drives steady erythropoiesis, which is the basis for the endurance and vascularity reputation. And it has a very long half-life, which means slow onset and a very long tail.

Pharmacokinetics and the 14-day half-life

The dataset records a half-life of 14 days, Cmax near 600 ng/dL, Tmax around 6 days, and bioavailability near 63%. That 14-day half-life is among the longest in this dataset, longer than testosterone enanthate (~7 days) and nandrolone decanoate (~10 days).

The practical consequences are significant. It takes weeks to reach steady serum levels, so EQ is a poor choice if you want fast results. Research protocols injected once or twice weekly, and the slow ramp means you feel little for the first few weeks. It also means that if side effects appear, they take weeks to resolve after stopping.

Use the peak-trough estimator to model the slow accumulation. This is a compound where patience is forced on you by the pharmacokinetics.

Research protocols used EQ in the 200 to 600 mg per week range, typically run for 12 weeks or longer because of the slow onset.

Erythropoiesis and hematocrit

This is the signature effect of boldenone and the main harm-reduction focus. EQ raises red blood cell production steadily. Over weeks, hematocrit climbs. This is the basis for the endurance and vascularity reports, but it is also a cardiovascular risk.

High hematocrit thickens blood, which raises blood pressure and increases the risk of clotting and stroke. Monitor hematocrit throughout any EQ run. If it exceeds 52 to 54%, the options are dose reduction, stopping, or phlebotomy (blood donation or therapeutic phlebotomy).

This effect is not unique to EQ, any androgen raises hematocrit to some degree. But boldenone is particularly noted for it. If you are running EQ alongside testosterone, the hematocrit effect compounds, since both raise RBC production.

Estrogenic activity and AI use

Boldenone aromatizes at roughly half the rate of testosterone. This means estrogenic side effects (water retention, gynecomastia risk) are less prominent than with a testosterone-only cycle, but they are not zero. The weaker aromatization also means you need less aromatase inhibitor coverage than you would on an equivalent testosterone dose.

The trap is over-using an AI. Because there is less estrogen to suppress, a standard dose of Arimidex or Aromasin can crash E2. Low E2 causes joint pain, libido loss, dry membranes, and mood disturbance. Symptom-driven dosing guided by E2 bloodwork is the approach, same as with any aromatizing compound.

Detection window: one of the longest

This is where EQ stands out. The 18-nor-17β-hydroxymethyl-17α-methyl-androst-1,4,13-trien-3-one long-term metabolite is detectable for a very long window, roughly 90 to 180 days per Pozo et al. (2012). Multi-dose regimens can extend this further.

If you are subject to doping control, EQ is a poor choice for that reason alone. The compound lingers in metabolite form for months after the last dose. This is harm-reduction context, not instructions for evading a test.

Side-effect profile summary

Boldenone is rated comparatively mild. It is not hepatotoxic. Lipid effects are present but less severe than oral AAS. The androgenic burden is lower than testosterone. HPTA suppression is real but slower in onset than with shorter esters.

The main monitoring priorities are hematocrit (the big one), blood pressure (driven partly by hematocrit), lipids, and estradiol. A standard hormone and metabolic panel covers these. See our reading bloodwork guide.

FAQ

How long does Equipoise take to work?

Because of the 14-day half-life, it takes 4 to 6 weeks to reach meaningful steady serum levels. Most users report feeling effects starting around week 4. This is a slow compound by design.

Does Equipoise aromatize?

Yes, but weakly, roughly half the rate of testosterone. Estrogenic side effects are possible but less prominent than with testosterone. Be careful not to over-use an AI, since crashing E2 is easy with a weakly aromatizing compound.

Why does Equipoise raise hematocrit so much?

Boldenone drives erythropoiesis (red blood cell production) more than most injectables. Over weeks, this raises hematocrit, which thickens blood and raises cardiovascular risk. Monitor hematocrit and act if it climbs above 52 to 54%.

How long is Equipoise detectable?

The long-term metabolite is detectable for roughly 90 to 180 days (Pozo 2012), among the longest windows in the dataset. This is for educational context, not test-beating guidance.

Is Equipoise good for cutting or bulking?

Both, depending on dose and stack. Its weak aromatization makes it useful in lean-gain and cutting contexts. The erythropoiesis effect appeals to endurance-focused users. Results are slow and modest compared to faster compounds like Dianabol.

Sources

• Pozo OJ, et al. Detection and characterization of boldenone metabolites in human urine. Journal of Steroid Biochemistry and Molecular Biology. 2012.
• World Anti-Doping Agency. Prohibited List. wada-ama.org.
• Van Dette E, Cornforth K. Pharmacokinetics of boldenone in the equine. Equine Veterinary Journal.
• Schänzer W, Donike M. Metabolism of boldenone in man. Biological Mass Spectrometry.